1 17 1

Partnering

MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.

Learn more

Corporate Overview

Corporate Fact Sheet
Home»Pipeline

Product Pipeline

MacroGenics has a diverse portfolio of proprietary product candidates with several clinical trials currently underway or planned for the near future.  Set forth below is the company's development pipeline.

 

Program (Target) Indication Partner Lead Optim. Pre-Clin. Phase 1 Phase 2 Phase 3
ONCOLOGY          
Margetuximab * (HER2) Gastroesophageal *  *  *  *  * 
Metastatic Breast *  *  *  *  * 
Solid Tumors *  *  *  *  * 
MGA271 ** (B7-H3) Solid Tumors *  *  *  *  * 
MGD006 ** (CD123 x CD3) AML *  *  *  *  * 
MGD007 ** (gpA33 x CD3) Gastrointestinal *  *  *  *  * 
Multiple DARTs   Various *  *  *  *  * 
AUTOIMMUNE          
Teplizumab  (CD3) T1D - At-Risk (NIH) *  *  *  *  * 
MGD010 *** (CD32B x CD79B) Lupus, RA *  *  *  *  * 

*Green Cross has marketing rights in Korea only.

**MacroGenics retains rights in U.S., Canada, Mexico, Japan, Korea & India.
Servier has option to license rights in ROW (MGD006 option has been exercised).

***Takeda has option to obtain exclusive worldwide license.  MacroGenics retains option to co-promote in U.S. and may fund portion of Phase 3 in exchange for North American profit share.

Major Rights Retained
Partnered Globally